Centessa Pharmaceuticals Plc Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2021

Location

Horsham PA US

Primary Industry

Pharmaceuticals

About

Founded in 2021, based in Pennsylvania, US, Centessa Pharmaceuticals Plc operates as a biopharmaceutical company that develops medicines and clinical programs to treat various diseases. In May 2021, Centessa became a public company with a total offering of USD 20.00 per ADS, under the ticker symbol CNTA. In October 2021, Centessa Pharmaceuticals Plc raised USD 300 million in venture debt funding led by new investor Oberland Capital Management. The firm applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry teams. Centessa Subsidiaries are comprised of ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, Pega-One, and Z Factor. The current company's portfolio consists of four clinical-stage programs, including two that are in late-stage clinical development, and more than 10 additional programs spanning diseases with unmet needs across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the management team. The company plans to invest resources in accordance with a follow-the-data strategy, that will have consolidated capabilities to allow the advancement of each Centessa Subsidiary's respective programs. Manufacturing, legislative, and organizational resources are all available to facilitate and expedite the scientific execution of programs by subsidiary teams.

Current Investors

T Rowe Price, General Atlantic, Venrock

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.centessa.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.